Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt–Jakob disease in the UK. Lancet 1996;347:921–5.
Collinge J, Sidle KCL, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 1996;383:685–90.
Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 1997;389:498–501.
Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997;389:448–50.
Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004;363:51–61.
Minor PD. Technical aspects of the development and validation of tests for variant Creutzfeldt–Jakob disease in blood transfusion. Vox Sanguinis 2004;86:164–70.
Wadsworth JDF, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt–Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001;358:171–80.
Bernoulli C, Siegfreid J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt–Jakob disease by surgery. Lancet 1977;i:478–9.
Fichet G, Comoy E, Duval C, et al. Novel methods for disinfection of prion-contaminated medical devices. Lancet 2004;364:521–6.
Trevitt CR, Singh PN. Variant Creutzfeldt–Jakob disease: pathology, epidemiology, and public health implications. Am J Clin Nutr 2003;78 (suppl) :651S–6S.
Brown P, Preece M, Brandel J-P, et al. Iatrogenic Creutzfeldt–Jakob disease at the millennium. Neurology 2000;55:1075–81.
Safar J, Wille H, Itri V, et al. Eight prion strains have PrPSc molecules with different conformations. Nat Med 1998;4:1157–65.
Bonn D. Future uncertain for reliable vCJD screening tests. Lancet 2000;356:228.
British Broadcasting Corporation. We may have a test for vCJD [BBC News]. 16 March 2004. http://news.bbc.co.uk/go/pr/fr/-/hi/health/3517184.stm (accessed 18 Mar 2004).
Blajchman MA, Goldman M, Webert KE, et al. Proceedings of a consensus conference: the screening of blood donors for variant CJD. Transfus Med Rev 2004;18:73–92.
The National Creutzfeldt-Jakob Disease Surveillance Unit. CJD figures. Update 6 Dec 2004. http://.www.cjd.ed.ac.uk (accessed 8 Dec 2004) [For specific up to date figures, http://www.cjd.ed.ac.uk/figures.htm ].
Llewelyn CA, Hewitt PE, Knight RSG, et al. Possible transmission of variant Creutzfeldt–Jakob disease by blood transfusion. Lancet 2004;363:417–21.
Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364:527–9.
Bird SM. Recipients of blood or blood products "at vCJD risk". BMJ 2004;328:118–9.
Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004;203:733–9.
Wells GA, Scott AC, Johnson CT, et al. A novel progressive spongiform encephalopathy in cattle. Vet Rec 1987;31:419–20.
Tan L, Williams MA, Khan MK, et al. Risk of transmission of bovine spongiform encephalopathy to humans in the United States: Report of the council of scientific affairs. JAMA 1999;281:2330–9.
Lord Phillips of Worth Matravers, Bridgeman J, Ferguson-Smith M. The BSE Inquiry: the inquiry into BSE and variant CJD in the United Kingdom. Oct 2000. http://www.bseenquiry.gov.uk/index.htm (accessed 8 Jan 2005).
Almond J, Pattison J. Human BSE. Nature 1997;389:437–8.
Brown P. On the origins of BSE [Commentary]. Lancet 1998;352:252–3.
Mishra RS, Basu S, Gu Y, et al. Protease-resistant human prion protein and ferritin are cotransported across Caco-2 epithelial cells: implications for species barrier in prion uptake from the intestine. J Neurosci 2004;24:11280–90.
Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001;24:519–50.
Will RG, Zeidler M, Stewart GE, et al. Diagnosis of new variant Creutzfeldt–Jakob disease. Ann Neurol 2000;47:575–82.
Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt–Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999;353:183–9.
Horby P. Variant Creutzfeldt–Jakob disease: an unfolding epidemic of misfolded proteins. J Paediatr Child Health 2002;38:539–42.
McDonnell G, Burke P. The challenge of prion decontamination. Clin Infect Dis 2003;36:1152–4.
Hunter M. Inquiry into handling of CJD alert welcomed. BMJ 2002;325:1055.
Collinge J. Variant Creutzfeldt–Jakob disease. Lancet 1999;354:317–23.
Sneath PHA. Estimation of the size of the vCJD epidemic. Antonie can Leeuwenhoek 2004;86:93–103.
Kmietowicz Z. Patients informed of increased risk of vCJD contact. BMJ 2004;329:702.
Spinney L. vCJD epidemic could be first of many, experts warn [News]. Nat Med 2003;9:1096.
Frosh A, Smith LC, Jackson CJ, et al. Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein. Lancet 2004;364:1260–2.
Myers R, Marans K, MacDonald M. Huntington’s disease. In: Wells R, Warren S, eds. Genetic instabilities and hereditary neurological diseases. San Diego, CA: Academic Press, 1998:301–23.
Delatycki MB, Tassicker R. Adult onset neurological disorders: predictive genetic testing. Aust Fam Physician 2001;30:948–52.
International Huntington Association and the World Federation of Neurology Research Group on Huntington’s Chorea. Guidelines for the molecular genetics predictive test in Huntington’s disease. J Med Genet 1994;31:555–9.
Binedell J, Soldan JR, Harper PS. Predictive testing for Huntington’s disease: predictors of uptake in South Wales. Clin Genet 1998;54:477–88.
Almqvist EW, Bloch M, Brinkman R, et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalisation after predictive testing for Huntington disease. Am J Hum Genet 1999;64:1293–304.
Bird T. Outrageous fortune: the risk of suicide in genetic testing for Huntington disease. Am J Hum Genet 1999;64:1289–92.
Sobel SK, Cowan DB. Impact of genetic testing for Huntington disease on the family system. Am J Med Genet 2000;90:49–59.
Meiser B, Dunn S. Psychological effects of genetic testing for Huntington’s disease: an update of the literature. West J Med 2001;174:336–40.
Human Genetics Commission (UK). Inside information: balancing interests in the use of personal genetic data. 2002; http://www.hgc.gov.uk (accessed 1 Feb 2005).
Gregori L, McCombie N, Palmer D, et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004;364:529–31